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Background: Migraine attacks occur spontaneously in those who suffer from the condition, but migraine-like
attacks can also be induced artificially by a number of substances. Previously published evidence makes the meninges
a likely source of migraine related pain. This article investigates the effect of several vasodilators on meningeal arteries
in order to find a connection between the effect of a substance on a meningeal vessel and its ability to artificially
induce migraine.
Methods: A myograph setup was used to test the vasodilator properties of the substances acetylcholine (ACh), sodium
nitroprusside (SNP), sildenafil, prostaglandin E2 (PGE2), pituitary adenylate cyclase activating peptide-38 (PACAP-38),
calcitonin gene-related peptide (CGRP) and NaCl buffer on meningeal arteries from human and rat. An unpaired t-test
was used to statistically compare the mean Emax(%) at the highest concentration of each substance to the Emax(%) of
NaCl buffer.
Results: In the human experiments, all substances except PACAP-38 had an Emax (%) higher than the NaCl buffer, but
the difference was only significant for SNP and CGRP. For the human samples, clinically tested antimigraine compounds
(sumatriptan, telcagepant) were applied to the isolated arteries, and both induced a significant decrease of the effect of
exogenously administrated CGRP. In experiments on rat middle meningeal arteries, pre-contracted with PGF2α, similar
tendencies were seen. When the pre-contraction was switched to K+ in a separate series of experiments, CGRP
and sildenafil significantly relaxed the arteries.
Conclusions: Still no definite answer can be given as to why pain is experienced during an attack of migraine. No
clear correlation was found between the efficacy of a substance as a meningeal artery vasodilator in human and the
ability to artificially induce migraine or the mechanism of action. Vasodilatation could be an essential trigger, but only
in conjunction with other unknown factors. The vasculature of the meninges likely contributes to the propagation of
the migrainal cascade of symptoms, but more research is needed before any conclusions can be drawn about the
nature of this contribution.
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The dura mater and its vasculature, the middle menin-
geal artery (MMA) and the venous system have for de-
cades been central to many hypotheses aimed to explain
migraine pathophysiology [1,2]. Ray and Wolff showed
in the 1940s that direct stimulation of the dura mater
may result in headache with migraine-like qualities [3].
Further research during the last two decades has demon-
strated that sensitization and local inflammation in the
dura mater can be elicited by various agents and stimu-
lation paradigms [4]. The local administration of an “in-
flammatory soup” or the direct stimulation at different
parts of the dura mater may result not only in vasoactive
responses but sometimes also in mast cell degranulation
and in plasma extravasation. Histamine, a major amine
released from mast cells, is known to induce a migraine-
like pain upon infusion into test subjects previously
diagnosed with migraine [5]. Some migraine-associated
symptoms, including the characteristic pain, could there-
fore stem from the activation of meningeal mast cells
and aseptic inflammation initiated by histamine release
[6]. However, local administration of calcitonin gene-
related peptide (CGRP), which is a sensory neuropeptide
in the dura mater and a known migrainogenic substance
[7], results only in vasodilatation [8]. Despite the fact
that mast cells have CGRP receptors [9,10], no activation
or sensitization of meningeal nociceptors could be de-
tected upon topical or systemic administration of this
compound in rats [8].
Apart from CGRP and histamine, other substances
that upon intravenous infusion can provoke migraine-
like attacks in humans previously diagnosed with migraine
are prostaglandin E2 (PGE2), pituitary adenylate cyclase
activating peptide-38 (PACAP-38), epoprostenol (prosta-
cyclin, PGI2), sildenafil and nitric oxide (NO) [11-15]. The
only common factor among these substances is their vaso-
dilator properties, but still there exist several other vasodi-
lators which do not induce migraine-associated symptoms
upon infusion. Vasoactive intestinal polypeptide (VIP) and
carbachol, both associated with the parasympathetic sys-
tem, are noted examples, although their ability to dilate
meningeal arteries in vivo remains to be verified [16,17].
This shows that factors apart from the vasodilatation have
to be taken into consideration. There is still controversy
regarding whether vasodilatation directly contributes to
any of the migraine-related symptoms or whether this is
just a side-phenomenon. Several hypotheses exist that
downplay the role of vasodilatation, including the obser-
vation of prodromal aura symptoms preceding any activ-
ity in the vasculature [18], that the vasoconstrictor triptan
drugs are not an effective treatment in all migraine patients
and that the extravascular tissue surrounding the dural
arteries could be too rigid to allow for any significant ex-
pansion of the vessel diameter [19].We have recently investigated the vasoactive effects of
several substances on cerebral arteries from human and
rat in vitro in order to find common denominators that
would allow us to understand more about the possible fac-
tors behind the migraine-associated symptoms [20]. How-
ever, cerebral arteries are different from meningeal arteries
regarding several morphological aspects, including recep-
tor expression, anatomical origin (internal carotid artery
(ICA) versus external carotid artery (ECA)) and the lack
of a blood–brain barrier (BBB) in the meningeal arteries
[21]. Nevertheless, both vascular regions receive sensory
input from the first division of the trigeminal ganglion
[22]. Therefore it is possible that the two artery types con-
tribute to migraine differently if there indeed is a vascular
component.
The aim of the present study is to evaluate whether
there is a connection between the ability of a substance
to dilate meningeal arteries and the previously reported
migrainogenic properties of each substance. It is useful
to verify whether vasodilatation of the meningeal arteries
indeed is the trigger for the migraine-like pain triggered
by these substances. Since the meningeal arteries lack BBB
properties, systemic drugs are freely diffusible to endothe-
lial and smooth muscle receptors to elicit a vasomotor re-
sponse. A secondary goal of this study is to compare the
functional aspect of the middle meningeal artery (MMA)
between the species because rat is often used in mechanis-
tic studies due to the difficulty in obtaining human tissue
samples.
Methods
The experimental protocol (M11104) was approved by
the Animal Protocol Review committee at the University
of Lund. All human artery procedures were carried out
strictly according to national laws and guidelines and ap-
proved by the Ethical Committee at the University of
Lund (LU-818-01) and the local Ethics Committee at the
Erasmus MC, Rotterdam.
Obtaining the MMA
A. Fresh samples of MMA were obtained from the men-
inges of male Sprague–Dawley rats by the following proced-
ure. The rats were anesthetized using CO2 and decapitated.
The cranium was opened from the top and the brain re-
moved, which exposed the dura mater. The cranium and
dura mater were divided sagitally and each half was placed
in a buffer solution composed of NaCl 119 mM, NaHCO3
15 mM, KCl 4.6 mM, MgCl2 1.2 mM, NaH2PO4 1.2 mM,
CaCl2 1.5 mM and glucose 5.5 mM. The dura mater was
carefully separated from the cranium and moved to a Petri
dish, where it was submerged in buffer solution, stretched
and suspended by needles. The MMA was removed from
the dura mater by a dissecting microscope, cut into seg-
ments 1–2 mm long that were placed in parallel tissue
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with a gas composed of 95% O2 and 5% CO2, with a result-
ing pH of 7.4 [23].
B. Human samples of intracranial MMA branches were
acquired from patients undergoing neurosurgery at the
University Hospital of Lund and the Erasmus University
Medical Center (Rotterdam, the Netherlands). The vessel
segments themselves were from visually healthy tissue.
The artery samples were upon removal immediately
placed in cold Dulbecco’s modified Eagle’s medium (DMEM,
Gibco, Invitrogen, Carlsbad, CA, USA) in Lund and in
cold medium M199 (Gibco, Invitrogen, Carlsbad, CA,
USA) in Rotterdam and immediately transported to the
laboratory where they were prepared in an identical way
to the rat MMA.
Myography
Each segment of MMA was mounted on a pair of thin
metal wires (human: 40 μm, rat: 20/25 μm) in an arterial
myograph. One wire was connected to a micrometer
screw, allowing for fine adjustment of the vascular tone
by varying the distance between the wires. The other
wire was connected to a force displacement transducer,
paired with an analogue-digital converter (ADInstruments,
Oxford, UK). Data was recorded on a computer using a
PowerLab unit (ADInstruments).
The aerated bicarbonate buffer was heated to +37°C
and used to submerge the wires with the MMA-segment
during the experiment. The segment was normalized,
attaining 90% of the internal circumference that a fully
relaxed vessel would have under a transmural pressure of
100 mmHg or 50 mmHg (see below). A reference value
for the contractile capacity of the segment was determined
by temporarily replacing part of the NaCl in the buffer
solution with 60 mM K+.
The effects on the segment of the different vaso-
active substances was tested by first recording the spon-
taneous resting diameter of the artery segment and define
it as the maximum dilatation possible. Next, the seg-
ment was pre-contracted with 10−6 M prostaglandin
F2α (PGF2α) to achieve a stable tension for the dur-
ation of the experiment. Finally, concentrations of the
tested substances in the range of 10−10-10−5 M (the exact
range varied between substances) were applied cumula-
tively and the vessel response was recorded. Because
of the unstable response to PGF2α in the first rat ex-
periments, we changed the protocol and used 30 mM K+
as a more stable contraction. In addition, the trans-
mural pressure was lowered to 90% of 50 mmHg in these
experiments.
Artery segments were omitted from the study if they
failed to fulfill the inclusion criteria. Segments included
in the final calculations were required to respond to ini-
tial testing with K+ and to the pre-contraction with amaximum contractile capacity of at least 1 mN for hu-
man arteries and 0.1 mN for rat arteries.Studies with clinically tested anti migraine compounds
The vessel segments were precontracted with 30 mM K+.
After precontraction the vessel segments were dilated with
4 nM CGRP. When a stable dilatation was achieved, su-
matriptan or telcagepant was added to the arteries in con-
centrations corresponding to the Cmax (160 nM and 5 μM,
for the 100 mg and 300 mg oral doses, respectively)
[24-26], as well as in concentrations corrected for plasma
protein binding. The Cmax for sumatriptan was corrected
for 17.5% plasma protein binding [27], while the Cmax for
telcagepant was calculated using a plasma protein binding
of 96.4% [28].Calculations
The maximum dilatory response (Emax(%)) for each tested
substance was obtained for the vessel segments as the
percentage tonus relaxed by the maximum concentra-
tion of substance from the PGF2α- or K
+-induced pre-
contraction towards the resting tonus sampled before
the lowest concentration of substance was added. In
the case of significant relaxation the negative logarithm
of the concentration of substance required for dilatation
of the vessel segments to half of their Emax(%). The pEC50
was obtained for the purpose of comparing the potency
of the different substances, calculated using GraphPad
Prism software (GraphPad Software, San Diego, California,
USA).
If a test subject contributed with more than one vessel
segment to the testing of a substance, all results obtained
from that individual regarding that substance were pooled
together into an average before further processing of data.
The hypothesis was that each substance would induce
vasodilatation and to determine the significance of the
dilatation an unpaired t test was performed using the
GraphPad Prism software (GraphPad Software, San Diego,
California, USA.) comparing the average Emax(%) of the
highest concentration of each substance to the average
Emax(%) of NaCl buffer at the end of the session.
Figures were compiled where it is shown how the
PGF2α/K
+ precontraction (100%) during a session is re-
stored towards the original resting baseline at different
concentrations of each of the substances tested and
NaCl buffer (Figures 1, 2, 3, 4, and 5). The contractile re-
sponses to telcagepant and sumatriptan were expressed as
percentage of the previous relaxant response to 4 nM
CGRP in the same segment (Figure 2). All data are
presented as mean ± S.E.M. Statistical analysis and
pEC50 calculations were performed using Graphpad
Prism 5 software. Statistical significance was accepted
at P < 0.05.
Figure 1 The effect of substances on human middle meningeal arteries precontracted with PGF2α. The relaxation relative to PGF2α
induced tone in human meningeal arteries by increasing concentrations of each of the tested substances (A-F) and NaCl buffer (G). Values are
given as mean ± SEM (n = 4 – 6), where PGF2α precontraction is set to be 100%.
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The vasoactive substances used in the present study
were: acetylcholine chloride (ACh), sodium nitroprusside
(SNP), sildenafil, PACAP-38 (all purchased from Sigma
Aldrich), PGE2 (Larodan fine Chemicals AB). The inhibi-
tors used were the following: Telcagepant (MK-0974)
(dissolved in DMSO and further diluted in H2O) (MSD,
Whitehouse Station, NJ, USA), sumatriptan (dissolved in
H2O) (Sigma Aldrich).Results
Functional results from the MMA
Intracranial MMA segments from 6 humans were used to
test the vasoactive properties of six different compounds
including NaCl buffer but excluding CGRP. The vessels
were divided into several segments of 1–2 mm in length
and studied in parallel tissue baths. Not every segment
was exposed to all compounds. Vessels from 4 additional
human patients were used for the testing of CGRP.
Figure 2 Effect of telcagepant and sumatriptan on CGRP
induced relaxation of the middle meningeal artery. Arteries
were precontracted with 30 mM K+, dilated with 4 nM CGRP and
sumatriptan or telcagepant was subsequently added (* = p < 0.05).
Values are given as % of the CGRP relaxation (mean ± SEM, n = 5).
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Of the compounds tested, SNP and CGRP on human
artery showed significant dilatation compared to NaCl, with
CGRP being the strongest vasodilator (Figure 1, Table 1).
ACh showed a non-significant tendency of relaxation.
PGE2, PACAP-38 and sildenafil showed no vasomotor ac-
tivity distinct from the gradual loss of pre-contraction
seen when using only NaCl buffer (Figure 1, Table 1). The
very high concentration of sildenafil (10 μM) was not
tested on human vessels.
Human MMA and CGRP (100 mmHg, pre-contracted with
30 mM K+)
For human samples the clinically tested anti migraine
compounds were applied to the isolated arteries that
that had been precontracted with 30 mM K+. CGRP in-
duced a significant vasodilatation of meningeal arteries
(84 ± 10% of precontraction with 30 mM K+). The con-
centrations corresponding to the Cmax obtained after oral
administration of 100 mg sumatriptan (160 nM) or
300 mg telcagepant (5 μM) both lead to a significant de-
crease of the effect of the exogenous administrated CGRP
(−8 ± 18% and 8 ± 8%, respectively) (Figure 2). Also the
concentrations of both sumatriptan and telcagepant cor-
rected for plasma protein binding abolished the effect of
exogenous CGRP (8 ± 36% for sumatriptan and 4 ± 7% for
telcagepant, respectively) (Figure 2).Rat MMA, (100 mmHg, pre-contracted with PGF2α)
SNP and sildenafil showed a tendency to relax the arter-
ies but the observed dilatation was not statistically sig-
nificant (Figure 3, Table 2). ACh, PGE2 and PACAP-38
did not display any discernible vasodilatation compared
to NaCl (Figure 3, Table 2). The results from these rat
experiments showed a larger spread compared to the ex-
periments using human artery segments or a different
protocol, and thus had a higher ratio of not passing the
inclusion criteria.
For the first experiments above, the same protocol as
for the human vessels (100 mmHg and pre-contracted
with PGF2α) was used to test all substances including
NaCl on MMA segments from 5 rats. These vessels
showed a large variation and had a high ratio of not
passing the inclusion criteria of 0.1 mN. Therefore, the
protocol was changed by lowering the transmural pressure
to 50 mmHg and the experiments were repeated using an
additional 5 rats. This markedly improved the success rate.
In addition, the MMAs pre-contracted with 30 mM K+,
did not have a negative drift over time (Figure 4A). A
sample relaxation to a cumulative dose of SNP is also
shown (Figure 4B).
Rat MMA, (50 mmHg, pre-contracted with 30 mM K+)
The results showed significant relaxation upon expos-
ure to SNP, CGRP and sildenafil compared to the NaCl
control group, SNP being the strongest vasodilatator
(Figure 5, Table 3). PGE2, ACh and PACAP-38 showed
no significant response compared to the control group
(Figure 5, Table 3). These results correlate with the ten-
dency seen for the above MMA.
Discussion
The addition of substances on human vessels was stud-
ied at a transmural pressure of 100 mmHg and pre-
contracted with PGF2α. Two different approaches for the
rat MMAs were used, and in this article the results from
both methods are presented. Lowering of the transmural
pressure from 100 mmHg to 50 mmHg greatly improved
the success rate, and the more constant 30 mM K+ pre-
contraction improved reproducibility. The gradual failing
of the PGF2α pre-contraction and increase of the K
+-
induced pre-contraction was mitigated by comparing the
vasomotor activity of the substances with the spontaneous
activity observed when subjecting the vessel segments to
only NaCl buffer. It is important to inform the reader, that
the isolation and insertion of wires into the rat MMA,
destroys the endothelial cell layer because of the small
diameter of the rat MMA (around 100 μm in o.d.). The
lack of endothelium can be seen in Figure 4A because
ACh induces a contraction, most likely acting on ACh re-
ceptors on the smooth muscle cells. The endothelial func-
tion in the human vessels is not substantial either, as no
Figure 3 The effect of substances on rat middle meningeal arteries precontracted with PGF2α. The relaxation induced in rat meningeal
arteries pre-contracted with PGF2α at increasing concentrations of each of the tested substances (A-E) and NaCl buffer (F). Values are given as
mean ± SEM (n = 3 – 5), where PGF2α precontraction is set to be 100%.
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endothelial function and the lack of sympathetic tone in
the vessels in this study could alter some of the effects
of the substances added. For example, sildenafil has
both endothelial-dependent and -independent effects
[29], which could be different in human and rat.
The results from both types of experiments on rat tis-
sue were consistent and showed that SNP, CGRP and
sildenafil induced vasodilatation, while ACh, PGE2 and
PACAP-38 had little effect. When used on human ves-
sels, the same myography method yielded significant
results for SNP and CGRP, where a strong dilatation
was observed. An alternative method that has been
used in rodents with some success is the cranial win-
dow method where substances can be applied topic-
ally through a thinned calvarium [30], but with this
method quantification is difficult, as the concentration
of active substance that reaches the vessel is difficult to
control, hence pEC50 and Emax cannot reliably be calcu-
lated. Further, there are more factors (e.g., blood pressure)
that can influence the results than when using isolated
vessels in vitro.For the experiments on human vessels, the greatest
difference in response between MMA and the previously
published data for MCA [20] was seen when subjecting
the vessels to sildenafil and PACAP-38, which in both
cases constituted a stronger dilatation in the MCA. This
was surprising in the case of sildenafil since there are
previous reports of rat MMA containing higher levels of
phosphodieterase type 5 (PDE5) than reported for rat
MCA [31]. If the same conditions were valid for human
vessels, the higher concentration of the target enzyme in
the MMA means that sildenafil should have had more
effect there. However, the effect is also dependent on
basal NO and cGMP levels, and we cannot rule out that
there could be an influence of the age of the human
compared to the rat vessels. In addition, the sympathetic
tone in vivo could be counteracted by increased NO
production, which would not occur in our setup. There-
fore, sildenafil could be effective in vivo, but not in the
myographs. It is hard to draw conclusions about the dif-
ference in Emax(%) of PACAP-38 due to previous con-
flicting observations of the activity of PACAP-38 in rat.
Previously published in vitro experiments where human
Figure 4 Comparison of 30 mM K+ and PGF2α on rat middle
meningeal arteries, and sample relaxation. A) Sample
contraction induced by of 30 mM K+ or PGF2α in rat meningeal
artery. One can observe the slight positive drift for 30 mM K+ and
slight the negative drift for PGF2α. B) Sample relaxation in an artery
precontracted with 30 mM K+ and the cumulative relaxation of
added sodium nitroprusside (SNP). Small plateaus were allowed
before next concentration was added.
Table 2 Rat MMA, 100 mmHg, pre-contracted with PGF2α
Compound Emax(%) pEC50 (M) p - value
ACh (n = 3) 33 ± 22 N.A. 0.68
SNP (n = 3) 70 ± 18 8.3 ± 0.7 0.066
Sildenafil (n = 3) 52 ± 20 ~7 0.23
PGE2 (n = 3) 23 ± 12 N.A. 0.82
PACAP-38 (n = 4) 22 ± 14 N.A. 0.93
NaCl (n = 3) 23 ± 4 N.A.
p-value for comparing agonist versus the NaCl effect. N.A. = Not Applicable.
Values are ± SEM, n given in parenthesis.
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gests that PACAP-38 could indeed dilate human MMA
(Emax(%) = 34 ± 12; pEC50 = 6.9 ± 0.1) [32] and that the
absence of vasodilatation observed in the rat experi-
ments in the present study is either due to lack of receptors
or technical issues. However, there is no data suggestingTable 1 Human MMA, 100 mmHg, pre-contracted with
PGF2α
Compound Emax(%) pEC50 (M) p - value
ACh (n = 6) 17 ± 6 N.A. 0.44
SNP (n = 6) 32 ± 6 ~3.5 0.034
Sildenafil (n = 6) 11 ± 2 N.A. 0.91
PGE2 (n = 6) 8 ± 1 N.A. 0.62
PACAP-38 (n = 5) 9 ± 3 N.A. 0.89
CGRP (n = 4) 62 ± 8 8.1 ± 0.19 0.0015
NaCl (n = 4) 10 ± 4 N.A.
p-value for comparing agonist versus the NaCl effect. N.A. = Not Applicable.
Values are ± SEM, n given in parenthesis.an endothelial response to PACAP-38. This suggests
that the rat is not a good model for studies of the
PACAP-38 mechanisms.
Previous in vivo studies exist where magnetic reson-
ance angiography (MRA) was used to measure the diam-
eter of the extracranial part of the MMA of live human
test subjects before, during and after spontaneous and
artificially induced episodes of migraine. Intravenous in-
fusion of CGRP [33], PACAP-38 [34] and nitroglycerine
[35] in healthy non-migraineurs were shown to increase
the diameter of the extracranial MMA. These substances
are known to induce a headache lacking the migraine-
related characteristics in non-migraineurs and this type
of pain coincided with the observed vascular dilatation.
When CGRP was infused to migraineurs, the results were
reproduced and an additional, migraine-like headache
with delayed onset occurred [36]. On the other hand,
spontaneous migraine attacks reported in patients were
associated with a modest increase in diameter (a magni-
tude of 11.4-13.0%) of the MCA and the intracranial parts
(cavernous and cerebral) of the ICA [37]. The intracranial
basilar artery (BA) and the extracranial vessels of ECA,
superficial temporal artery (STA), the cervical part of the
ICA and the extracranial part of the MMA were not sig-
nificantly dilated.
Migraine-aborting triptan drugs had a constricting ef-
fect on arteries outside of the BBB, like the MMA and
the extracranial part of the ICA, but not on cerebral ar-
teries including the intracranial part of the ICA. Regard-
less of whether an episode of migraine was triggered
naturally or by an infused substance, the pain was miti-
gated and the extracranial MMA contracted from the
use of triptan drugs. However, it should be noted that
these studies did not include the intracranial branches of
the MMA, which is the source of the vessel segments
used presently in the in vitro studies, and it is still un-
known how this part of the artery would be affected
in vivo by a spontaneous episode of migraine or a thera-
peutic dose of sumatriptan. The question is relevant, be-
cause all arteries shown to significantly dilate during an
episode of migraine are all intracranial. Intracranial
meningeal arteries would be unique in that they are both
Figure 5 The effect of substances on rat middle meningeal arteries precontracted with K+. The relaxation induced in rat meningeal arteries
pre-contracted with K+ at increasing concentrations of each of the tested substances (A-F) and NaCl buffer (G). Values are given as mean ± SEM
(n = 5), where 30 mM K+ precontraction is set to be 100%).
Table 3 Rat MMA, 50 mmHg, pre-contracted with
30 mM K+
Compound Emax(%) pEC50 (M) p - value
ACh (n = 5) −26 ± 13 N.A. 0.85
SNP (n = 5) 67 ± 22; 6.1 ± 1.3 0.015
Sildenafil (n = 5) 40 ± 17 5.7 ± 3.8 0.0069
PGE2 (n = 5) −31 ± 5 N.A. 0.311
PACAP-38 (n = 5) 27 ± 8 N.A. 0.94
CGRP (n = 5) −1 ± 6 ~ 8 0.0015
NaCl (n = 5) −24 ± 5 N.A.
p-value for comparing agonist versus the NaCl effect. N.A. = Not Applicable.
Values are ± SEM, n given in parenthesis.
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a type of artery that could possibly be both dilated during
an episode of migraine and contracted by drugs. In the
in vitro study presented here, the effect of two well-known
clinically tested anti migraine compounds were applied to
the isolated human MMAs. Both sumatriptan (5-HT re-
ceptor agonist) and telcagepant (a CGRP receptor antagon-
ist) significantly reduced the CGRP induced vasodilation.
This shows that the vasoactive clinically tested compounds
can exert their effect directly on the MMA.
In vivo experiments in rat, using the cranial window
method to directly view and apply substances to the
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results to the in vivo observations in human regarding
the extracranial part of the vessel. The MMA of rats was
significantly dilated by α- and βCGRP [38,39], sildenafil
[31], VIP, PACAP-38, PACAP-27 [40], histamine [41]
and ACh [42]. VIP is interesting in that it is not a
migrainogenic substance [16]. It has not been established
what effect VIP could have on human isolated MMA
in vivo, but since VIP is known to dilate human MMA
branches in vitro [32] one can assume that the in vivo
effect would mirror that found in the rat. Vasodilatation
without migraine-related pain speaks against the dilation
of the MMA as a direct cause of the pain. As with the
effect of other substances on meningeal arteries, there
are conflicting reports regarding VIP. No significant dila-
tation was observed during in vitro experiments using
the myography method on the MMA [43]. Using the
pressurized arteriography method cerebral and MMA
were found to relax to the addition of VIP and PACAP
[44,45]. PACAP was more potent than VIP [44] while
the reverse was seen in the cerebral artery [45].
When the vasomotor responses from our experiments
are compared with the migrainogenic properties of the
tested substances, there seems to be little correlation be-
tween the ability of a substance to induce migraine-like
attacks and their vasoactive properties in human menin-
geal arteries. Sildenafil, PGE2 and PACAP-38 showed no
tendency of dilatation of the arteries in the current
study, despite having known migrainogenic properties.
One may wonder why and how the migrainogenic sub-
stances induce headache if vasodilatation of meningeal
or cerebral arteries is not the mechanism. Endothelial
nitric oxide (NO) is not the key molecule since the intra-
cellular pathways activated by the migrainogenic sub-
stances CGRP and PACAP-38 are not dependent of NO in
the cranial vessels [20]. The remaining factors are the peri-
vascular and dural nerve fibers. It has been shown before
that the dura mater contains a rich supply of sensory sub-
stance P and CGRP fibers, and of sympathetic noradren-
aline and neuropeptide Y, but only a minor amount of
parasympathetic VIP and PACAP containing fibers [46]. It
is tentative to suggest that local release or systemic admin-
istration of the various substances may modify the activity
of the dural nerve fibers via specific receptors or mecha-
nisms. This clearly deserves future attention.
Conclusion
The lack of correlation between the vasoactive and
migrainogenic properties of the tested substances leads
us to the conclusion that direct vasodilatation of intra-
cranial meningeal arteries is most likely not the sole trig-
ger of the artificial migraine-like pain experienced by
migraine sufferers upon infusion of these substances into
the blood stream. This opinion is based on the fact thatseveral migrainogenic substances induced no significant
vasodilatation when applied in vitro to human meningeal
arteries. We can however not rule out that the cranial
pain and migrainogenic properties associated with the
infusion of these substances could have a relation to cra-
nial vasodilation in vivo. The in vivo vasodilatory responses
to the substances could be affected by the vascular tone,
endothelial interplay and the activation of perivascular
nerve fibers around the dural arteries or in the trigeminal
ganglion.
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